Anand D Jeyasekharan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2306543/publications.pdf

Version: 2024-02-01

471061 253896 2,110 47 17 43 citations h-index g-index papers 56 56 56 3359 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	ROS and the DNA damage response in cancer. Redox Biology, 2019, 25, 101084.	3.9	1,068
2	Biomarkers for Homologous Recombination Deficiency in Cancer. Journal of the National Cancer Institute, 2018, 110, 704-713.	3.0	223
3	Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes. Haematologica, 2018, 103, 278-287.	1.7	82
4	Molecular pathogenic pathways in extranodal NK/T cell lymphoma. Journal of Hematology and Oncology, 2019, 12, 33.	6.9	82
5	TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell, 2021, 184, 2618-2632.e17.	13.5	80
6	LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition. PLoS ONE, 2015, 10, e0118002.	1.1	67
7	Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer, 2022, 25, 741-750.	2.7	42
8	Predicting synthetic lethal interactions using heterogeneous data sources. Bioinformatics, 2020, 36, 2209-2216.	1.8	37
9	NF-κB signaling mediates acquired resistance after PARP inhibition. Oncotarget, 2015, 6, 3825-3839.	0.8	35
10	Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study. Frontiers in Oncology, 2016, 6, 274.	1.3	32
11	Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. EMBO Molecular Medicine, 2021, 13, e13366.	3. 3	30
12	Real world experience of Râ€CHOP with or without consolidative radiotherapy vs DAâ€EPOCHâ€R in the firstâ€line treatment of primary mediastinal Bâ€cell lymphoma. Cancer Medicine, 2019, 8, 4626-4632.	1.3	29
13	The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation. International Journal of Molecular Sciences, 2018, 19, 1931.	1.8	28
14	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Gut, 2022, 71, 1277-1288.	6.1	23
15	Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma. Blood Cancer Journal, 2020, 10, 9.	2.8	22
16	Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut, 2022, 71, 676-685.	6.1	21
17	PRDM15 is a key regulator of metabolism critical to sustain B-cell lymphomagenesis. Nature Communications, 2020, 11, 3520.	5 . 8	20
18	CEACAM6 is upregulated by <i>Helicobacter pylori</i> CagA and is a biomarker for early gastric cancer. Oncotarget, 2016, 7, 55290-55301.	0.8	17

#	Article	IF	Citations
19	Combination of vaccine-strain measles and mumps virus synergistically kills a wide range of human hematological cancer cells: Special focus on acute myeloid leukemia. Cancer Letters, 2014, 354, 272-280.	3.2	16
20	Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Oncotarget, 2016, 7, 64089-64099.	0.8	16
21	A bio-functional polymer that prevents retinal scarring through modulation of NRF2 signalling pathway. Nature Communications, 2022, 13, 2796.	5.8	16
22	Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. Clinical Cancer Research, 2020, 26, 5320-5328.	3.2	14
23	Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders. Frontiers in Pediatrics, 2019, 6, 405.	0.9	12
24	DNA damage signalling as an anti-cancer barrier in gastric intestinal metaplasia. Gut, 2020, 69, 1738-1749.	6.1	11
25	Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy. PLoS ONE, 2016, 11, e0164319.	1.1	9
26	Quantitative Analysis of a Multiplexed Immunofluorescence Panel in T-Cell Lymphoma. SLAS Technology, 2018, 23, 252-258.	1.0	9
27	Profiling of gastric cancer cell-surface markers to achieve tumour–normal discrimination. BMJ Open Gastroenterology, 2020, 7, e000452.	1.1	6
28	Reversal of Bowel Obstruction With Platinum-Based Chemotherapy and Olaparib in Recurrent, Short Platinum-Free Interval, RAD51C Germline Mutation–Associated Ovarian Cancer. JCO Precision Oncology, 2018, 2, 1-8.	1.5	5
29	Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature. Expert Review of Hematology, 2019, 12, 1095-1105.	1.0	5
30	PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production. Oncogene, 2022, 41, 1986-2002.	2.6	5
31	A patient with pembrolizumab-induced fatal polymyositis. European Journal of Cancer, 2018, 91, 180-182.	1.3	4
32	Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma. Journal of Visualized Experiments, 2019, , .	0.2	4
33	A genomicâ€augmented multivariate prognostic model for the survival of naturalâ€killer/Tâ€cell lymphoma patients from an international cohort. American Journal of Hematology, 2022, 97, 1159-1169.	2.0	4
34	PARP inhibitors need an extra STING for therapeutic efficacy. Science Translational Medicine, 2019, 11, .	5.8	3
35	Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 167, 103507.	2.0	3
36	A Robust Protocol for CRISPR as9 Gene Editing in Human Suspension Cell Lines. Current Protocols, 2021, 1, e286.	1.3	3

#	Article	IF	CITATIONS
37	p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain). Oncogene, 2022, 41, 2106-2121.	2.6	3
38	The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2019, 60, 3214-3224.	0.6	2
39	Emergency drug use in a pandemic: Harsh lessons from COVID-19. Cell, 2021, 184, 5497-5500.	13.5	2
40	PD-L2 in follicular lymphoma: Sidekick or star?. Science Translational Medicine, 2019, 11, .	5.8	2
41	Treatment outcomes of T and naturalâ€killer/Tâ€eell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy. Cancer Reports, 2022, , e1552.	0.6	2
42	Life-threatening Bleed Secondary to Tumor Shrinkage Effectively Palliated with Radiotherapy . Cureus, 2017, 9, e1386.	0.2	1
43	JAK-ing up antibody delivery to cancer. Science Translational Medicine, 2019, 11, .	5.8	1
44	Recycling resected tonsils for lymphoma research. Science Translational Medicine, 2019, 11 , .	5.8	0
45	The "cancer flu shot�. Science Translational Medicine, 2020, 12, .	5.8	O
46	An Algorithm to Mine Therapeutic Motifs for Cancer from Networks of Genetic Interactions. IEEE Journal of Biomedical and Health Informatics, 2022, PP, 1-1.	3.9	0
47	T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival. PLoS ONE, 2022, 17, e0261469.	1.1	O